MedTrace Logo

Comparison of Efficacy and Safety Between Imidafenacin and Fesoterodine in Patients With Overactive Bladder

NCT01578304 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 207

Last updated 2012-04-16

No results posted yet for this study

Summary

To evaluate the efficacy and safety after 12 weeks oral administration of Imidafenacin 0.1mg b.i.d versus Fesoterodine 4mg once daily for the urge incontinence and/or increased urinary frequency associated with urgency as may occur in patients with overactive bladder.

Conditions

Interventions

DRUG

Imidafenacin

Tablet, 12 weeks twice daily

DRUG

Fesoterodine

Tablet, 12 weeks once daily

Sponsors & Collaborators

  • Kyorin Pharmaceutical Co.,Ltd

    collaborator INDUSTRY

  • LG Life Sciences

    lead INDUSTRY

Principal Investigators

  • KYU-SUNG LEE, M.D. · Samsung Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01578304 on ClinicalTrials.gov